An Inhibitor of DRP1 (Mdivi-1) Alleviates LPS-Induced Septic AKI by Inhibiting NLRP3 Inflammasome Activation

Abstract

Mitochondria play an essential role in energy metabolism. Oxygen deprivation can poison cells and generate a chain reaction due to the free radical release. In patients with sepsis, the kidneys tend to be the organ primarily affected and the proximal renal tubules are highly susceptible to energy metabolism imbalances. Dynamin-related protein 1 (DRP1) is an essential regulator of mitochondrial fission. Few studies have confirmed the role and mechanism of DRP1 in acute kidney injury (AKI) caused by sepsis. We established animal and cell sepsis-induced AKI (S-AKI) models to keep DRP1 expression high. We found that Mdivi-1, a DRP1 inhibitor, can reduce the activation of the NOD-like receptor pyrin domain-3 (NLRP3) inflammasome-mediated pyroptosis pathway and improve mitochondrial function. Both S-AKI models showed that Mdivi-1 was able to prevent the mitochondrial content release and decrease the expression of NLRP3 inflammasome-related proteins. In addition, silencing NLRP3 gene expression further emphasized the pyroptosis importance in S-AKI occurrence. Our results indicate that the possible mechanism of action of Mdivi-1 is to inhibit mitochondrial fission and protect mitochondrial function, thereby reducing pyroptosis. These data can provide a potential theoretical basis for Mdivi-1 potential use in the S-AKI prevention.

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Sepsis has become the primary cause of AKI in patients. Infection in patients with chronic renal insufficiency often leads to further deterioration of renal function [1]. Currently, more attention is being paid to preventing AKI. Kidney replacement therapy is the only alternative when patients have severe electrolyte disorders, such as water and sodium retention, azotemia, hepatorenal syndrome, and other life-threatening pathophysiological changes [2].

The kidney receives 20% of the cardiac output. Nevertheless, its oxygen consumption corresponds to 10% of the body’s oxygen consumption [3]. In addition, the kidney has the second highest mitochondrial content and oxygen consumption after the heart. Mitochondrial function can be severely affected and impaired by the compensatory range of cells and cellular damage caused by various factors, such as ischemia and hypoxia, toxin stimulation, heavy metal ions, and chemotherapy drugs. Thus, ATP synthesis decreases, causing a cell energy metabolism disorder and, subsequently, cell death [4]. Reactive oxygen species (ROS) produced by energy metabolism can initiate key cellular pathways, such as ROS/P38, ROS/Akt, and ROS/c-Jun N-terminal kinase (JNK). On the other hand, mitochondrial DNA (mtDNA) released by mitochondrial damage can trigger the mtDNA/interferon gene (STING) expression and stimulate the mtDNA/Caspase-1/3 signaling pathway, which are closely linked to increased cell death [5, 6].

Dynamin-related protein 1 (DRP1) is a cytoplasmic protein that can aggregate on the mitochondrial surface and induce mitochondrial division by interacting with mitochondrial fission protein 1 [7, 8]. Recent studies have shown that DRP1 inhibitors and knockout can significantly reduce renal ischemia-reperfusion injury in animal models [9]. Excessive mitochondrial division can lead to impaired cell function and increased release of apoptotic substances into mitochondria, which is detrimental to cells. Pyroptosis is characterized by lytic cell death Caspase-1 or Caspase-11 induced in mouse cells, which in turn leads to GSDMD-induced pore formation and cleavage of inflammatory procytokine interleukin-1β (IL-1β) and interleukin-18 (IL-18). Pyroptosis differs from other programmed cell death modes because it promotes the release of large amounts of proinflammatory factors that recruit a greater participation of inflammatory cells, thereby expanding the inflammatory response [10, 11]. This inflammatory pathway is widely found in macrophages, monocytes, and other immune cells, as well as in some nonimmune cells, including epithelial cells [12]. Our previous studies in animal models have shown that NOD-like receptor pyrin domain-3 knockout improves kidney function and inhibits inflammation in mice [13]. Several studies have proven that both ROS and mtDNA contribute to mitochondrial fever by activating the NLRP3 inflammasome [14]. Consequently, as per previous studies, by suppressing DRP1 expression, various mitochondrial functions have been improved, including increased mitochondrial membrane potential, increased mtDNA copy number, and decreased mitochondrial ROS [15]. Given this, we present a study to assess whether it is possible, by reducing the release of mitochondrial content, to protect mitochondrial function, inhibit pyroptosis, and consequently promote kidney function protection.

2. Materials and Methods

2.1. Animals

Male wild-type C57BL6 mice, 6-8 weeks old, weighing 20 to 25 g, taken from the River of Life laboratory in Beijing, were kept at constant temperature and humidity ($22\pm 1^{°}\text{C}$ and $50\pm 10\%$, respectively) and under a 12 h light/dark cycle in a laboratory animal care facility with free access to food and water. TheS-AKI mouse model was constructed by an intraperitoneal injection of 5 mg/kg lipopolysaccharide (LPS, E. coli O111: B4, Sigma, USA) according to previous reports [16]. Mdivi-1 (Sigma, USA) was properly dissolved in dimethyl sulfoxide (DMSO) and administered intraperitoneally at a dose of 3 mg/kg one hour before LPS injection. Mice were randomly assigned to 4 experimental groups ($n=6$ per group): vehicle control group (mouse body weight of $5\text{mg}/\text{kg}0.9\%\text{saline}+3\text{mg}/\text{kg}\text{DMSO}$), vehicle Mdivi-1 group ($5\text{mg}/\text{kg}0.9\%\text{saline}+3\text{mg}/\text{kg}\text{Mdivi}-1$), S-AKI control group ($5\text{mg}/\text{kg}\text{LPS}+3\text{mg}/\text{kg}\text{DMSO}$), and S-AKI+Mdivi-1 treatment group ($5\text{mg}/\text{kg}\text{LPS}+3\text{mg}/\text{kg}\text{Mdivi}-1$). After 24 hours, the mice were anesthetized with preconfigured mixed anesthetic, the eyeballs were removed, blood was collected, and the renal tissue was perfused and also collected. In order to ensure mouse stability, reduce the pain of the animals, and obtain analgesic and sedative effects, 80 mg/kg of ketamine (Jiangsu Hengrui, China) combined with 12 mg/kg of xylazine (Sigma, USA) was used as a mixed anesthetic. After total infusion with 0.9% saline, the right kidney of the mice was isolated and placed in 4% paraformaldehyde for 24 hours for hematoxylin-eosin (HE) staining. Each experimental group contained at least three right kidneys. The left kidney was divided into two lobes longitudinally centered on the renal hilum. The renal medulla was separated from the cortex, and after separation, a part of the renal cortex was placed at -80°C for Western blot and enzyme-linked immunosorbent assay (ELISA) analyses. The other part was placed in liquid nitrogen for mitochondrial separation and purification within 30 minutes. Each experimental group contained 6 left kidneys. The collected blood was placed in EDTA tubes and centrifuged at 4000 g for 15 min. The resulting plasma was stored at -80°C. The anesthesia and execution of mice followed the animal ethics standards of Harbin Medical University.

2.2. Cell Culture and Treatment

Mouse renal tubular epithelial (TCMK-1) cells, an immortalized cell line purchased from the American Type Culture Collection (ATCC), were cultured with DMEM/F12 containing 10% fetal bovine serum (Gibco, USA) in a constant temperature incubator at 37°C, 5% CO₂, and 95% air. The S-AKI cell model was constructed by adding 5 μg/ml LPS to the cell culture dish that was maintained for 12 hours. This model was already established and evaluated several times in the literature [17]. The Mdivi-1 (10 μM) effect was evaluated in renal tubular epithelial cells, which were divided into four groups: vehicle control group, vehicle Mdivi-1 group, LPS control group, and LPS Mdivi-1 group. LPS was added 60 minutes after Mdivi-1 addition, and both were incubated together for another 12 hours. TCMK-1 cells were first inoculated into 6-well plates, and after the culture density reached 10⁵ per well, they were transfected with 8 μl of blank adenoviral vector or siNLRP3 adenovirus for 4 hours. To reduce errors, pretests were performed in advance. The cultured cells were marked at different culture time points and counted using a cell counting plate to find the exact moment when the 10⁵ cell density was reached. For siRNA/siNLRP3 transfection experiments, the cells were washed three times with PBS, and fetal calf serum was added for further 48 hours of incubation. Cell viability was determined by a Cell Counting Kit 8 (CCK-8) assay kit (Beyotime, China) according to the manufacturer’s protocol. Apoptosis analysis of cells was performed by flow cytometry and by using an Annexin V PE/7-AAD apoptosis detection kit (Solarbio, China). Annexin V-positive and 7-AAD-negative cells were defined as apoptotic cells.

2.3. Mitochondrial Function Determination

Mitochondria from kidney tissue and renal tubular epithelial cells were isolated using a Mitochondria Isolation Kit (Invitrogen, USA) according to the manufacturer’s protocol. Isolated mitochondrial protein concentration was determined by the Bradford method. Mitochondrial function was defined by analyzing the mitochondrial membrane potential (ΔΨm) and mitochondrial ROS content. ΔΨm was measured in isolated mitochondria using the JC-1 (Invitrogen, USA). 100 μg of purified mitochondria was added to the JC-1 staining solution in a 96-well plate for fluorescence determination, using 490 and 530 nm as excitation and emission wavelengths, respectively. The fluorescent measures were obtained in the SpectraMAX M5 reader, and the ΔΨm was obtained by calculating the fluorescence units per milligram of protein. In cell experiments, ΔΨm changes were observed by confocal microscopy.

Mitochondrial ROS activity was measured with MitoSOX Red (Invitrogen, USA), a redox-sensitive fluorescent probe that is selectively targeted to mitochondria. 50 μg of isolated mitochondrial protein was incubated with MitoSOX solution (containing 5 μM of the probe) for 30 minutes at 37°C and 5% CO₂. The red fluorescence was determined using excitation and emission wavelengths of 510 and 580 nm, respectively, in a fluorescence plate reader. The data statistics are expressed in terms of fluorescence per milligram of protein.

2.4. Western Blot Analysis

The protein was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (8% SDS-PAGE). The protein in the gel was transferred to a polyvinylidene fluoride (PVDF) membrane by wet transfer, and 50 g/l skim milk was blocked for 2 hours. DRP1, gasdermin D (GSDMD), Caspase-1, NLRP3, and GAPDH antibodies (Abcam, USA) were incubated overnight at 4°C, and the membrane was washed 3 times with phosphate-buffered solution+Tween-20 (PBST). The corresponding secondary anti-rabbit antibody (1 : 10000) was incubated for 1 hour at room temperature, and the membrane was washed again with PBST. The detection of specific protein bands was performed by ECL, which were analyzed using ImageJ software.

2.5. Serum Creatinine (sCr) Determination

The determination of sCr in mice was performed using ELISA kits (Cloud Clone Corp, China) according to the manufacturer’s instructions.

2.6. Determination of Malondialdehyde (MDA), Superoxide Dismutase (SOD), and Adenosine Triphosphate (ATP)

To detect the oxidative stress level in kidney tissue, colorimetric detection of MDA and SOD levels was performed by a kit (Beyotime Biotechnology, China) after homogenization of the renal tissue. In addition, the energy metabolism of cells was detected by determining the intracellular ATP level using a luciferase-based assay according to the manufacturer’s instructions (Jiancheng, China).

2.7. HE Staining and Tubular Damage Score Measurement

Renal tissues were fixed with paraformaldehyde (4%) for 24 hours, paraffin-embedded, and sectioned at a thickness of 4 μm. Then, they were processed for HE staining and evaluated using a light microscope (Olympus, Japan). The severity of the renal tubular injury was assessed using Paller et al.’s method [18].

2.8. GTPase Activity Assay of DRP1

To detect that the Mdivi-1 mechanism of action inhibits the DRP1 GTPase activity, instead of causing nonspecific effects of DRP1, the GTPase activity assay of DRP1 was performed in the control and Mdivi-1 treatment groups. First, the DRP1 protein was separated from TCMK-1 cells by immunoprecipitation. The Mdivi-1 treatment group received Mdivi-1 doses of 1, 5, and 10 μM for 12 hours before protein extraction. The control group received a considerable volume of phosphate-buffered saline (PBS, Beyotime Biotechnology, China) solution and waited for the same time before protein extraction. After extracting the total cellular protein, 2 μg of DRP1 antibody was added per 500 μg of protein and rotated at 4°C overnight. Subsequently, 50 μl of protein A/G-beads was added to different antigen-antibody mixtures and rotated at 4°C for 4 h. Then, this mixture was washed twice with RIPA lysis and extraction buffer and after was washed three times with GTPase buffer (2.5 μM MgCl 2.50 μM Tris-HCl pH 7.5). Subsequently, 0.5 mM GTP (Beyotime Biotechnology, China) was added and incubated at 30°C for 30 minutes. Finally, the GTPase activity measurement kit (Sigma, USA) was used according to the manufacturer’s protocol, and the absorbance value obtained at 620 nm with a SpectraMAX M5 reader was identified as the relative DRP1 GTPase activity amount.

2.9. Statistical Analysis

The measurement data used are in the form of $\text{mean}\pm \text{Standard}\text{Error}\text{of}\text{Mean}$ (SEM). SPSS 21.0 statistical software was used for analysis. A one-way ANOVA was used to compare between groups. GraphPad Prism software (v10.0a) was used for drawing graphics. $P<0.05$ was statistically significant.

3. Results

3.1. DRP1 Was Upregulated in LPS-Induced S-AKI Mouse Model

Firstly, an S-AKI model was built in mice by intraperitoneal injection of LPS. The LPS application resulted in a significant increase in the creatinine level in septic mice ($P<0.05$ for S-AKI control versus vehicle; Figure 1(a)). The degree of tubular edema and renal tubular injury scores showed by HE staining was significantly higher compared to that of the control group (Figures 1(b) and 1(c)). HE staining also shows that the renal tubules in the S-AKI group presented obvious edema, which was relieved after intervention with Mdivi-1. In addition, after Mdivi-1 injection in sepsis AKI mice, the serum creatinine level and renal tubular injury score decreased significantly ($P<0.05$ for S-AKI+Mdivi-1 versus S-AKI control; Figures 1(a) and 1(c)). Western blot analysis showed there was no difference in DRP1 expression in whole cells between the different groups ($P>0.05$ for S-AKI versus vehicle; Figure 1(d)). However, DRP1 expression in mitochondria was significantly upregulated in the S-AKI control group ($P<0.05$ for S-AKI control versus vehicle; Figure 1(e)). Mdivi-1 administration improved both renal damage and tubular edema damage degrees ($P<0.05$ for S-AKI+Mdivi-1 versus S-AKI control; Figure 1(e)). These data suggest that DRP1 is a S-AKI effector and that Mdivi-1 can partially alleviate kidney damage in S-AKI mice.

[figures omitted; refer to PDF]

3.2. Mdivi-1 Downregulates NLRP3 Inflammasome Pathway Protein Expression and Protects Mitochondrial Function

The Mdivi-1 effects on the NLRP3 inflammasome protein expression in kidney tissue were assessed by Western blot analysis. The expression of NLRP3 inflammasome-related proteins (NLRP3, GSDMD, cl.Caspase-1, IL-1β, and IL-18) is significantly increased in the S-AKI group ($P<0.05$ for S-AKI control versus vehicle; Figures 2(a) and 2(b)). Remarkably, Mdivi-1 administration decreases significantly the expression of these proteins ($P<0.05$ for S-AKI+Mdivi-1 versus S-AKI control; Figures 2(a) and 2(b)). Oxidative stress damage of the renal tissue was also measured, and the MDA and SOD levels were higher in the S-AKI group ($P<0.05$ for S-AKI control versus vehicle; Figures 2(c) and 2(d)). However, Mdivi-1 administration can partially alleviate oxidative damage in S-AKI mice ($P<0.05$ for S-AKI+Mdivi-1 versus S-AKI control; Figures 2(c) and 2(d)). In addition, the mitochondrial function was evaluated by analyzing the mitochondrial membrane potential (ΔΨm) and mitochondrial ROS content. ΔΨm decreased and the MitoROS level increased in the LPS-induced group, but these effects were reduced after Mdivi-1 administration ($P<0.05$ for S-AKI+Mdivi-1 versus S-AKI control; Figures 2(e) and 2(f)). These data show that inhibition of DRP1 expression reduces the NLRP3 inflammasome activation, which reduces the oxidative damage of kidney tissue in sepsis mice, possibly by protecting the mitochondrial function.

[figures omitted; refer to PDF]

3.3. DRP1 Is Upregulated in LPS-Stimulated Renal Tubular Epithelial Cells

A S-AKI cell model was constructed to further validate the critical role of DRP1 in the NLRP3 inflammatory pathway. For this, different time points in TCMK-1 cell culture and different LPS concentrations were tested to verify cell viability. Finally, 5 μg/ml LPS ($P<0.05$ versus the level of LPS is 0 μg/ml; Figure 3(a)) and 12 hours of culture ($P<0.05$ versus time point is 0 hours; Figure 3(b)) were the best parameters chosen. The mitochondrial DRP1 protein expression was detected by Western blot and showed that the dose and time point of LPS application were feasible (Figures 3(c) and 3(d)). In addition, it was evaluated whether Mdivi-1 could specifically inhibit DRP1 in HK-2 cells. Thus, the immunoprecipitated DRP1 protein was incubated with GTP, and a measurement kit was used to detect GTPase activity. It was found that the GTPase activity was significantly reduced when the concentration of Mdivi-1 was 10 μM ($P<0.05$ versus the control group; Figure 3(e)).

[figures omitted; refer to PDF]

3.4. Mdivi-1 Downregulates the Expression of NLRP3 Inflammasome

A 10 μM dose of Mdivi-1 applied to renal tubular epithelial cells was able to significantly downregulate the expression of NLRP3-associated proteins compared to the LPS-stimulated group, as revealed by the Western blot assay ($P<0.05$ for LPS-treated cells versus vehicle; Figures 4(a) and 4(b)). Analysis by confocal microscopy revealed that both ΔΨm and green fluorescence on the confocal surface decreased after Mdivi-1 administration ($P<0.05$ for LPS+Mdivi-1 versus LPS control; Figures 4(c) and 4(e)). In addition, fluorescent analysis showed that Mdivi-1 administration also induced a reduction in the MitoROS level ($P<0.05$ for LPS+Mdivi-1 versus LPS control; Figure 4(d)) and in the red-stained material after MitoSOX Red assay (Figure 4(f)). Finally, intracellular ATP level measurement showed that the energy level increased after Mdivi-1 treatment ($P<0.05$ for LPS+Mdivi-1 versus LPS control; Figure 4(g)). These data again indicate that pathway protein expression of the NLRP3 inflammasome can be attenuated by inhibiting DRP1 expression, possibly by protecting mitochondrial function.

[figures omitted; refer to PDF]

3.5. siNLRP3 Downregulates NLRP3 Inflammasome Pathway Protein Expression and Apoptosis

To further validate the role of the NLRP3 inflammasome in cells, siRNA was transfected into renal tubular epithelial cells and the expression of NLRP3 inflammasome-related proteins was subsequently evaluated. Western blot assays showed that the expression of pyroptosis pathway proteins, NLRP3, GSDMD, cl.Caspase-1, IL-1β, and IL-18, was significantly reduced ($P<0.05$ for LPS+siNLRP3 versus LPS-treated cells; Figures 5(a) and 5(b)). In addition, siNLRP3 transfection also decreased the amount of apoptotic cells, as detected by flow cytometry analysis ($P<0.05$ for LPS+siNLRP3 versus LPS-treated cells; Figures 5(c) and 5(d)). These data indicate that inhibition of the NLRP3 gene expression can reduce apoptosis and that NLRP3 inflammasome-related proteins play an important role in LPS-induced pyroptosis.

[figures omitted; refer to PDF]

4. Discussion

Mitochondria undergo great changes during AKI [19]. In particular, the early mitochondrial function cannot be corrected, resulting in mitochondrial function imbalances that may lead to cellular energy metabolism disorders and various pathophysiological changes. In recent years, in addition to cell necrosis and apoptosis, other programmed cell death pathways, such as ferroptosis, autophagy, and pyroptosis [20], have been found to play an essential role in the AKI pathogenesis. These cell death pathways are closely related to mitochondrial dysfunction. Therefore, a complete molecular understanding of mitochondrial damage has become an area of exploration for the development of novel therapies for AKI. As the first cause of AKI in ICU patients, S-AKI have attracted increasing attention in recent years [21].

The general dynamic characteristics of mitochondria are relatively well described. In a changing environment, mitochondria can react to different states and fuse into rod-like or ring-like structures. In these situations, the mitochondrial network remains tightly connected and the mitochondria are always in a dynamic equilibrium of fusion-division in almost all cells [22]. However, it is only in recent years that mitochondrial dynamics changes specifically in renal tubular epithelial cells have become more prominent [23], which may be related to the fact that most of mitochondrial dynamics have been performed on the fibrous skeleton of cardiomyocytes. Previous studies have shown that renal tubular epithelial cells contain a large number of mitochondrial fusion-division-related proteins [24]. It is speculated that mitochondrial fusion and division may also play an essential role in maintaining myocardial cell homeostasis. DRP1 is undoubtedly an essential protein in the process of mitochondrial division and fusion. ATP depletion in energy metabolism can lead to overactivation of DRP1, causing mitochondrial division [25, 26]. Drug-induced injury in the tubular epithelial cell model and ischemia-reperfusion injury model assays showed a sharp increase in DRP1 expression. At the same time, DRP1 inhibitor administration improves the mitochondrial function and reduces apoptosis [27]. Recent studies have shown that mitochondrial damage, including mitochondrial volume release, is related to several cell events, including autophagy, pyroptosis, or other programmed cell death mechanisms [28, 29], not limited to apoptosis.

Pyroptosis is a new type of cell death that differs from the other programmed cell death types in that it causes the release of inflammatory mediators. It is more classically activated by NLRP3 inflammatory bodies, causing downstream Caspase-1 cleavage and release of IL-1β and IL-18. Remarkably, excessive inflammatory factor release aggravates body injury [30].

In our study, we first constructed animal and cell models of S-AKI. DRP1 was overexpressed, and mitochondrial function was severely damaged in both models. The mitochondrial function damage includes a significant decrease in mitochondrial membrane potential and a large amount of mitochondrial ROS production. In addition, the MDA and SOD levels, which can reflect the oxidative damage of tissue, also increased significantly. Administration of Mdivi-1, a drug that has been reported to inhibit DRP1 [31], resulted in mitochondrial dysfunction protection and reduced expression of pyroptosis pathway proteins. Moreover, Mdivi-1 treatment promoted a reduction in creatinine levels and a significant improvement in the renal function of the animals. In addition, MDA and SOD levels also decreased significantly compared to the S-AKI group, indicating that the oxidative damage in kidney tissue was improved after Mdivi-1 treatment. Thus, we can draw a preliminary conclusion that improving mitochondrial function is useful for protecting renal function in mice. By protecting mitochondrial function, NLRP3 inflammasome-mediated pyroptosis is also significantly inhibited. We further demonstrated the critical role of pyroptosis in the S-AKI model by inhibiting the expression of NLRP3 inflammatory bodies through siNLRP3 transfection. After knocking down the NLRP3 gene, the expression of NLRP3 inflammasome-mediated pyroptosis pathway proteins, including NLRP3, GSDMD, Caspase-1, IL-1β, and IL-18, was downregulated to varying degrees. In addition, flow cytometry analysis showed that cell numbers that have undergone apoptosis were greatly reduced, highlighting the importance of this pathway.

It is undeniable that there are some points in this study that should be improved and considered. First, the treatment of S-AKI by Mdivi-1 is only partially repairing as it does not totally reduce the ROS production. Moreover, the antioxidant properties of Mdvi-1 described here are not the result of direct effects. Its mechanism of reducing tissue oxidative damage is to regulate mitochondrial fission-division by decreasing the DRP1 protein expression. Recently, some direct-acting compounds targeting mitochondria have been identified, such as MitoQ and Mito-TEMPO, which have proven to show a good antioxidant effect in the animal and cell models of AKI [32, 33]. Therefore, future studies may be performed to evaluate the antioxidant effects of the combination of Mdivi-1 with these compounds on AKI. In addition, although our results showed that Mdivi-1 administration can inhibit the GTPase activity of the DRP1 protein, a previous study has suggested that the inhibitory effect of Mdivi-1 on DRP1 can be nonspecific [34]. This study indicated that the inhibitory effect of Mdvi-1 is not achieved by affecting the GTPase activity but by inhibiting the complex I-dependent respiration-related pathway. Therefore, further studies are needed to verify whether Mdvi-1 can be used routinely for the DRP1 inhibition or whether it will be necessary to develop more efficient and specific inhibitors. Nevertheless, despite these limitations, we identified in this study a potential mechanism of reducing S-AKI by Mdivi-1 administration, which is based on mitochondrial function protection and NLRP3 inflammasome-mediated pyroptosis reduction.

5. Conclusion

DRP1 is highly expressed in the renal cortex of S-AKI animals, and after Mdivi-1 administration, its expression was significantly reduced. This Mdivi-1 effect may be due to the protection of mitochondrial function and the reduction of the NLRP3 inflammasome-mediated pyroptosis of renal tubular epithelial cells. This study suggests that Mdivi-1 may be a potential treatment or preventive agent for S-AKI.

Authors’ Contributions

Kaijiang Yu conceived and designed the experiments. Ruijin Liu, Ming Li, and Sicong Wang performed the experiments. Ruijin Liu, Yue Bu, Xiaohui Ma, and Xiaonan Jia analyzed the data. Ruijin Liu, Ming Li, and Sicong Wang contributed the reagents. Ruijin Liu and Lei Sun wrote the paper. All authors have read and approved the final manuscript.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (grants 81571871 and 81770276).

References

[1] A. Zarjou, A. Agarwal, "Sepsis and acute kidney injury," Journal of the American Society of Nephrology, vol. 22 no. 6, pp. 999-1006, DOI: 10.1681/ASN.2010050484, 2011.

[2] S. Gaudry, J.-P. Quenot, A. Hertig, S. D. Barbar, D. Hajage, J.-D. Ricard, D. Dreyfuss, "Timing of renal replacement therapy for severe acute kidney injury in critically ill patients," American Journal of Respiratory and Critical Care Medicine, vol. 199 no. 9, pp. 1066-1075, DOI: 10.1164/rccm.201810-1906CP, 2019.

[3] P. Bhargava, R. G. Schnellmann, "Mitochondrial energetics in the kidney," Nature Reviews Nephrology, vol. 13 no. 10, pp. 629-646, DOI: 10.1038/nrneph.2017.107, 2017.

[4] P. Duann, P. H. Lin, "Mitochondria damage and kidney disease," Advances in Experimental Medicine & Biology, vol. 982,DOI: 10.1007/978-3-319-55330-6_27, 2017.

[5] K. Inoue, K. Nakada, A. Ogura, K. Isobe, Y.-i. Goto, I. Nonaka, J.-I. Hayashi, "Generation of mice with mitochondrial dysfunction by introducing mouse mtDNA carrying a deletion into zygotes," Nature Genetics, vol. 26 no. 2, pp. 176-181, DOI: 10.1038/82826, 2000.

[6] I. Jorgensen, M. Rayamajhi, E. A. Miao, "Programmed cell death as a defence against infection," Nature Reviews Immunology, vol. 17 no. 3, pp. 151-164, DOI: 10.1038/nri.2016.147, 2017.

[7] T. Wai, T. Langer, "Mitochondrial dynamics and metabolic regulation," Trends in Endocrinology and Metabolism, vol. 27 no. 2, pp. 105-117, DOI: 10.1016/j.tem.2015.12.001, 2016.

[8] W. W. Sharp, Y. H. Fang, M. Han, H. J. Zhang, Z. Hong, A. Banathy, E. Morrow, J. J. Ryan, S. L. Archer, "Dynamin-related protein 1 (Drp1)-mediated diastolic dysfunction in myocardial ischemia-reperfusion injury: therapeutic benefits of Drp1 inhibition to reduce mitochondrial fission," The FASEB Journal, vol. 28 no. 1, pp. 316-326, DOI: 10.1096/fj.12-226225, 2013.

[9] H. M. Perry, L. Huang, R. J. Wilson, A. Bajwa, H. Sesaki, Z. Yan, D. L. Rosin, D. F. Kashatus, M. D. Okusa, "Dynamin-related protein 1 deficiency promotes recovery from AKI," Journal of the American Society of Nephrology, vol. 29 no. 1, pp. 194-206, 2018.

[10] T. Strowig, J. Henao-Mejia, E. Elinav, R. Flavell, "Inflammasomes in health and disease," Nature, vol. 481 no. 7381, pp. 278-286, DOI: 10.1038/nature10759, 2012.

[11] K. Schroder, J. Tschopp, "The Inflammasomes," Cell, vol. 140 no. 6, pp. 821-832, DOI: 10.1016/j.cell.2010.01.040, 2010.

[12] K. T. Cheng, S. Xiong, Z. Ye, Z. Hong, A. di, K. M. Tsang, X. Gao, S. An, M. Mittal, S. M. Vogel, E. A. Miao, J. Rehman, A. B. Malik, "Caspase-11–mediated endothelial pyroptosis underlies endotoxemia-induced lung injury," Journal of Clinical Investigation, vol. 127 no. 11, pp. 4124-4135, DOI: 10.1172/JCI94495, 2017.

[13] Y. Cao, D. Fei, M. Chen, M. Sun, J. Xu, K. Kang, L. Jiang, M. Zhao, "Role of the nucleotide-binding domain-like receptor protein 3 inflammasome in acute kidney injury," FEBS Journal, vol. 282 no. 19, pp. 3799-3807, DOI: 10.1111/febs.13379, 2015.

[14] M. Lamkanfi, V. M. Dixit, "Mechanisms and functions of inflammasomes," Cell, vol. 157 no. 5, pp. 1013-1022, DOI: 10.1016/j.cell.2014.04.007, 2014.

[15] M. Hasnat, Z. Yuan, M. Naveed, A. Khan, F. Raza, D. Xu, A. Ullah, L. Sun, L. Zhang, Z. Jiang, "Drp1-associated mitochondrial dysfunction and mitochondrial autophagy: a novel mechanism in triptolide-induced hepatotoxicity," Cell Biology and Toxicology, vol. 35 no. 3, pp. 267-280, DOI: 10.1007/s10565-018-9447-8, 2019.

[16] Y. Chen, S. Jin, X. Teng, Z. Hu, Z. Zhang, X. Qiu, D. Tian, Y. Wu, "Hydrogen sulfide attenuates LPS-induced acute kidney injury by inhibiting inflammation and oxidative stress," Oxidative Medicine and Cellular Longevity, vol. 2018,DOI: 10.1155/2018/6717212, 2018.

[17] W. Huang, X. Lan, X. Li, D. Wang, Y. Sun, Q. Wang, H. Gao, K. Yu, "Long non-coding RNA PVT1 promote LPS-induced septic acute kidney injury by regulating TNF α and JNK/NF- κ B pathways in HK-2 cells," International Immunopharmacology, vol. 47, pp. 134-140, DOI: 10.1016/j.intimp.2017.03.030, 2017.

[18] M. S. Paller, J. R. Hoidal, T. F. Ferris, "Oxygen free radicals in ischemic acute renal failure in the rat," Journal of Clinical Investigation, vol. 74 no. 4, pp. 1156-1164, DOI: 10.1172/JCI111524, 1984.

[19] D. Martin-Sanchez, O. Ruiz-Andres, J. Poveda, S. Carrasco, P. Cannata-Ortiz, M. D. Sanchez-Niño, M. R. Ortega, J. Egido, A. Linkermann, A. Ortiz, A. B. Sanz, "Ferroptosis, but not necroptosis, is important in nephrotoxic folic acid–induced AKI," Journal of the American Society of Nephrology, vol. 28 no. 1, pp. 218-229, DOI: 10.1681/asn.2015121376, 2016.

[20] A. Linkermann, G. Chen, G. Dong, U. Kunzendorf, S. Krautwald, Z. Dong, "Regulated cell death in AKI," Journal of the American Society of Nephrology, vol. 25 no. 12, pp. 2689-2701, DOI: 10.1681/ASN.2014030262, 2014.

[21] M. Schetz, J. Prowle, "Focus on acute kidney injury 2017," Intensive Care Medicine, vol. 44 no. 11, pp. 1992-1994, DOI: 10.1007/s00134-018-5357-8, 2018.

[22] P. Mishra, D. C. Chan, "Metabolic regulation of mitochondrial dynamics," Journal of Cell Biology, vol. 212 no. 4, pp. 379-387, DOI: 10.1083/jcb.201511036, 2016.

[23] A. M. Hall, C. D. Schuh, "Mitochondria as therapeutic targets in acute kidney injury," Current Opinion in Nephrology and Hypertension, vol. 25 no. 4, pp. 355-362, DOI: 10.1097/MNH.0000000000000228, 2016.

[24] M. Tran, D. Tam, A. Bardia, M. Bhasin, G. C. Rowe, A. Kher, Z. K. Zsengeller, M. R. Akhavan-Sharif, E. V. Khankin, M. Saintgeniez, S. David, D. Burstein, S. A. Karumanchi, I. E. Stillman, Z. Arany, S. M. Parikh, "PGC-1 α promotes recovery after acute kidney injury during systemic inflammation in mice," Journal of Clinical Investigation, vol. 121 no. 10, pp. 4003-4014, DOI: 10.1172/JCI58662, 2011.

[25] F. Emma, G. Montini, S. M. Parikh, L. Salviati, "Mitochondrial dysfunction in inherited renal disease and acute kidney injury," Nature Reviews Nephrology, vol. 12 no. 5, pp. 267-280, DOI: 10.1038/nrneph.2015.214, 2016.

[26] S. G. Cho, Q. du, S. Huang, Z. Dong, "Drp1 dephosphorylation in ATP depletion-induced mitochondrial injury and tubular cell apoptosis," American Journal of Physiology-renal Physiology, vol. 299 no. 1, pp. F199-F206, DOI: 10.1152/ajprenal.00716.2009, 2010.

[27] Z. Liu, H. Li, J. Su, S. Xu, F. Zhu, J. Ai, Z. Hu, M. Zhou, J. Tian, Z. Su, P. Yang, J. Nie, "Numb depletion promotes Drp1-mediated mitochondrial fission and exacerbates mitochondrial fragmentation and dysfunction in acute kidney injury," Antioxidants & Redox Signaling, vol. 30 no. 15, pp. 1797-1816, DOI: 10.1089/ars.2017.7432, 2019.

[28] L. Huang, X.-h. Liao, H. Sun, X. Jiang, Q. Liu, L. Zhang, "Augmenter of liver regeneration protects the kidney from ischaemia-reperfusion injury in ferroptosis," Journal of Cellular and Molecular Medicine, vol. 23 no. 6, pp. 4153-4164, DOI: 10.1111/jcmm.14302, 2019.

[29] G. Biczo, E. T. Vegh, N. Shalbueva, O. A. Mareninova, J. Elperin, E. Lotshaw, S. Gretler, A. Lugea, S. R. Malla, D. Dawson, P. Ruchala, J. Whitelegge, S. W. French, L. Wen, S. Z. Husain, F. S. Gorelick, P. Hegyi, Z. Rakonczay, I. Gukovsky, A. S. Gukovskaya, "Mitochondrial dysfunction, through impaired autophagy, leads to endoplasmic reticulum stress, deregulated lipid metabolism, and pancreatitis in animal models," Gastroenterology, vol. 154 no. 3, pp. 689-703, DOI: 10.1053/j.gastro.2017.10.012, 2018.

[30] H. H. Szeto, S. Liu, Y. Soong, S. V. Seshan, L. Cohen-Gould, V. Manichev, L. C. Feldman, T. Gustafsson, "Mitochondria protection after acute ischemia prevents prolonged upregulation of IL-1 β and IL-18 and arrests CKD," Journal of the American Society of Nephrology, vol. 28 no. 5, pp. 1437-1449, DOI: 10.1681/ASN.2016070761, 2017.

[31] M. Ding, N. Feng, D. Tang, J. Feng, Z. Li, M. Jia, Z. Liu, X. Gu, Y. Wang, F. Fu, J. Pei, "Melatonin prevents Drp1-mediated mitochondrial fission in diabetic hearts through SIRT1-PGC1 α pathway," Journal of Pineal Research, vol. 65 no. 2,DOI: 10.1111/jpi.12491, 2018.

[32] A. J. Dare, E. A. Bolton, G. J. Pettigrew, J. A. Bradley, K. Saeb-Parsy, M. P. Murphy, "Protection against renal ischemia-reperfusion injury in vivo by the mitochondria targeted antioxidant MitoQ," Redox biology, vol. 5, pp. 163-168, DOI: 10.1016/j.redox.2015.04.008, 2015.

[33] M. J. Kong, S. H. Bak, K.-H. Han, J. I. Kim, J.-W. Park, K. M. Park, "Fragmentation of kidney epithelial cell primary cilia occurs by cisplatin and these cilia fragments are excreted into the urine," Redox Biology, vol. 20, pp. 38-45, DOI: 10.1016/j.redox.2018.09.017, 2019.

[34] E. A. Bordt, P. Clerc, B. A. Roelofs, A. J. Saladino, L. Tretter, V. Adam-Vizi, E. Cherok, A. Khalil, N. Yadava, S. X. Ge, T. C. Francis, N. W. Kennedy, L. K. Picton, T. Kumar, S. Uppuluri, A. M. Miller, K. Itoh, M. Karbowski, H. Sesaki, R. B. Hill, B. M. Polster, "The putative Drp1 inhibitor mdivi-1 is a reversible mitochondrial complex I inhibitor that modulates reactive oxygen species," Developmental Cell, vol. 40 no. 6, pp. 583-594.e6, DOI: 10.1016/j.devcel.2017.02.020, 2017.